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Introduction
Kaposi sarcoma (KS) is an angioproliferative disease
characterized by proliferation of mesenchymal cells
with formation of vascular spaces surrounded by spin-
dle-shaped cells and inflammatory cells. Evidence for
an infectious etiology has accumulated since the dis-
covery of a novel herpesvirus within KS lesions, called
human herpesvirus 8 (HHV8) or KS-associated her-
pesvirus (KSHV) (1). Infection with HHV8 has been
shown to precede development of KS (2) and expres-
sion of HHV8-encoded genes has been detected in KS
lesions (3). HHV8 encodes various genes with possible
transforming or angiogenic properties, including viral
homologues of cyclin-D, IL-6, interferon regulatory
factors, BCL-2, FLICE-inhibitory protein, three
chemokines (vMip-I, vMip-II, and vMip-III), and a G
protein–coupled receptor (referred to as KSHV —
vGPCR or ORF74) (4). Expression of ORF74 in trans-
fected cells has been shown to mediate cell prolifera-
tion and induce the secretion of VEGF, a potent angio-
genic factor expressed within KS lesions (5). It has been
suggested that ORF74-expressing cells could con-
tribute to the pathogenesis of KS, possibly through
paracrine mechanisms (5, 6). This hypothesis was
strongly supported by our recent observation that
transgenic mice expressing ORF74 under the control
of the human CD2 promoter develop angiogenic
lesions that have a striking resemblance to human KS
lesions, thereby implicating this virally encoded
chemokine receptor in the pathogenesis of KS (7).
ORF74 signals constitutively through a phospholipase
C pathway leading to increased phosphatidylinositol
turnover and activation of c-Jun N-terminal kinase and
p38 mitogen–activated protein kinase (8). The constitu-
tive activity of ORF74 is regulated by a broad spectrum
of CXC chemokines that bind this receptor with high
affinity. These chemokines can act as agonists, increas-
ing the constitutive signaling of the receptor; neutral lig-
ands, with no impact on signaling; or, as inverse agonists,
decreasing the high constitutive signaling activity (9, 10).
Interestingly, ligands that act as agonists on this virally
encoded receptor, are angiogenic chemokines such as
GROα, whereas the ligands that act as inverse agonists
are angiostatic chemokines such as IP-10 and SDF-1α
(10, 11). The CXC chemokines IL-8 and ENA78, which
also bind with high affinity to ORF74, are neutral lig-
ands that do not affect the signaling of the receptor.
Because KS lesions are highly vascularized and because
the signaling activity of ORF74 appears to be regulated
by angiogenic and angiostatic chemokines, it could be
suggested that fine-tuning of the constitutive activity of
ORF74 may be important for the angiogenic and
tumorigenic properties of the receptor.
We have previously generated mutant forms of
ORF74 in which properties such as constitutive activi-
ty, chemokine binding, and agonist activity were selec-
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tively eliminated (12). In the present study we describe
the generation and analysis of a number of transgenic
lines expressing these ORF74 mutants. We demonstrate
that not only the high constitutive signaling activity of
ORF74, but also the modulation of this activity by
endogenous chemokines, are required for the develop-
ment of the KS-like disease in transgenic mice.
Methods
Mice. Transgenic mice expressing HHV8 ORF74 have
been described by Yang et al. (7), and the construction
of mutated forms of HHV8 ORF74 have been described
by Rosenkilde et al. (12). Briefly, the wild-type and
mutant forms of ORF74 described by Rosenkilde et al.
(12) (Figure 1) were cloned into a hCD2 promoter-driv-
en vector (7) and their sequence verified using an Alf-
express sequencer (Amersham Pharmacia Biotech, Pis-
cataway, New Jersey, USA). Generation of transgenic
founders was done as described previously by pronu-
clear injection of C57Bl/6J × DBA/J F2 eggs (7). Trans-
genic animals (L91D, ∆22, CDVG, R2H) were mated to
C57Bl/6J × DBA/J F1. Transgenic offspring were iden-
tified by PCR amplification of a segment of the ORF74
gene using the following primers: 5′-TGGAACGTTG-
GAATACTCTCTCTG-3′ and 5′-AGGTACCTCACTAGACT-
GACGCAC-3′. As an internal control for the amplifica-
tion, reaction primers for the endogenous LDL gene
were used (5′-ACCCAAGACGTGCTCCCAGGATGA3′;
5′CGCAGTGCTCCTCATCTGACTTGT-3′). These primers
amplify a 250-bp segment of the transgene and a 
397-bp segment of the LDL gene. Animals were kept
under specific pathogen-free conditions, and experi-
ments followed institutional guidelines.
IP3 turnover. COS-7 cells were grown at 10% CO2 at
37°C in DMEM 1885 with 10% FCS, 2 mM glutamine,
and 0.01 mg/ml gentamycin added. Cells (5 × 105 per
well) were transfected with 40 µg of plasmid DNA
using the calcium precipitation method. One day after
transfection the cells were incubated with 5 µCi of 3H-
myo-inositol per milliliter of inositol-free media for 24
hours. Cells were washed twice in HEPES buffer sup-
plemented with 140 mM NaCl, 5 mM KCl, 1 mM
MgSO4, 1 mM CaCl2, 10 mM glucose, and 0.05%
(wt/vol) BSA. Cells were then incubated for 90 minutes
in HEPES buffer supplemented with 10 mM LiCl in
the presence of chemokines. Cells were extracted with
10% perchloric acid and incubated on ice for 30 min-
utes. Supernatants were neutralized with KOH in
HEPES buffer. 3H-inositol phosphates were purified
on AG 1-x8 anion-exchange resin (13). Determinations
were made in duplicate.
RNA analysis. Thymuses or lesional tissues were dis-
sected, frozen in liquid nitrogen or on dry ice, and RNA
isolated using Tri-Reagent (Molecular Research Center
Inc., Cincinnati, Ohio, USA) as instructed by the manu-
facturer, except for an additional extraction step in Tri-
Reagent. For transgene expression analysis 15 µg of
total thymus RNA was run on a 1% agarose gel and blot-
ted onto a Genescreen membrane (NEN Life Science
Products Inc., Boston, Massachusetts, USA). A 
1-kb PCR fragment of the HHV8 ORF74 DNA was
labeled with 32P (Amersham Pharmacia Biotech) and
used as a probe. For detection of chemokine and ORF74
expression within control and lesional tissue cDNA was
synthesized from 2 µg total RNA primed with oligo-
(dT)12-18 using the Superscript II Preamplification Sys-
tem (Invitrogen Corp., Carlsbad, California, USA) as
described by the manufacturer. Five microliters of
cDNA (2 µl for GAPDH) was amplified in a 50-µl reac-
tion volume using the following conditions: 94°C for 1
minute, then 35 cycles at 94°C for 1 minute, 60°C for 1
minute, 72°C for 2 minutes, incubated in a gene Amp
PCR System (Applied Biosystems, Foster City, Califor-
nia, USA). The oligonucleotide primers corresponding
to the sense and antisense strands, respectively, were as
follows: ORF74, 5′-ATGGCGGCCGAGGATTTCCTAACC-
3′ and 5′-AGGTACCTCACTAGACT-GACGCAC-3′; KC, 5′-
GTCCCGCTGACCAAGAGTCTT-3′ and 5′-GGCACT-
GACAGCGCAGCT-3′; SDF-1α, 5′-CGTGAGGCCAGGGA-
AGAGT-3′ and 5′-TGATGAGCATGGTG-GGTTGA-3′; MIP-
2, 5′-CCTGCCAAG-GGTTGACTTCA-3′ and 5′-TTCT-
GTCTGGGCGCAGTG-3′; IP-10, 5′-GACGGTCCGCTG-
CAACTG-3′ and 5′-GCTTCCCTATGGCCCTCATT-3′; and
GAPDH, 5′-TGAAGGTCGGTGTGA ACGGATTTGGC-3′
and 5′-CATGTAAGGCCATGAGGTCCACCAC-3′. The final
PCR products were analyzed on a 2% agarose gel con-
taining ethidium bromide.
Flow cytometry. Single cell suspensions were prepared
from the thymus by passage through a 100-µM nylon
cell strainer (Becton Dickinson Labware, Franklin
Lakes, New Jersey, USA) in RPMI medium containing
10% FCS. Cells (105 to 106) were incubated with 3%
heat-inactivated mouse serum (Sigma Chemical Co., St.
Louis, Missouri, USA) in 1× PBS, 1% BSA, and 0.1%
sodium azide for 10 minutes at 4°C. The cells were
stained with a rat mAb specific for the N-terminus of
ORF74 (clone 7D1). This mAb was made according to
methods described recently (14) and its generation will
be reported elsewhere (F. Cifire and M. Lipp, unpub-
lished observations). Thymocytes expressing ORF74
were detected using mouse anti-rat IgG-FITC Ab (212-
096-102; Jackson ImmunoResearch Laboratories Inc.,
West Grove, Pennsylvania, USA) at 0.2 mg/ml final con-
centration. To determine viability, samples were subse-
quently stained with 20 µl of 5 µg/ml propidium iodide
(Calbiochem-Novabiochem International, San Diego,
California, USA). Events were acquired on a Becton
Dickinson FACSCalibur (Becton Dickinson Immuno-
cytometry Systems, Mansfield, Massachusetts, USA)
and analyzed using the CellQuest software.
Histology. Fresh mouse tissues were fixed in 10% phos-
phate-buffered formalin and processed for paraffin sec-
tions. Paraffin sections (5 µm) were prepared and
stained with hematoxylin and eosin (H&E).
Statistical analysis. The significance of angioprolifera-
tive disease incidence between different transgenic ani-
mals was determined by likelihood comparisons, com-
paring homogeneity across groups (null hypothesis)
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with intergroup heterogeneity, given the following stip-
ulations. (a) The groups are represented by grouped
founders and lines of CDVG, R2H, ∆22, and L91D ani-
mals. (b) The binomial probability of disease develop-
ment varies between lines in different transgenes. (c)
Disease incidence within lines falls in three risk classes
with disease probability values of 0, intermediate, and
1. Thus the null (alternative) hypothesis claims that the
four transgenic categories have the same potential to
develop angioproliferative disease as reflected in the
mix of the three risk classes and the magnitude of the
intermediate risk involved.
Results
ORF74 is responsive to endogenous mouse chemokines. ORF74
binds a number of human CXC chemokines (6, 9, 10),
and, as demonstrated previously, is constitutively active.
In vitro experiments have shown that phosphoinositol
(PI) turnover levels observed in cells transfected with
ORF74 are 5.4-fold above control cells transfected with
an empty expression vector (12). To study the biological
activities of mutant forms of this receptor in transgenic
mice we first determined the ability of the wild-type
ORF74 to react with the corresponding mouse
chemokine ligands in vitro. To study the interaction of
murine chemokines with the wild-type receptor we
focused on murine homologues of chemokines known
to alter the signaling of ORF74. Thus, initially we used
the murine CXC chemokines, MIP-2 and KC, which are
most closely related to the preferred ORF74 agonist,
GROα. MIP-2 stimulated inositol phosphate turnover
in COS-7 cells transiently transfected with the wild-type
ORF-74 to the same degree as human GROα (Figure
1b). In contrast, the murine peptide KC had no effect in
this system. Both murine IP-10 and murine SDF-1α
acted as inverse agonists in a manner similar to their
human counterparts (Figure 1b).
We next examined the ability of the murine
chemokines to affect different ORF74 mutants (Figure
1a). Deletion of amino acids in the amino-terminal
region of ORF74 has been shown previously to elimi-
nate the ability of human chemokines to affect PI
turnover (12, 15). One such mutant (∆22-ORF74) has
been shown to have high constitutive activity and to
not respond to chemokines (12). Here we show that
none of the murine chemokines tested affected the
high constitutive activity of the ∆22-ORF74 mutant
(Figure 1b). The [R208H;R212H]ORF74 mutant (Fig-
ure 1a) has been shown previously to have high consti-
tutive activity equivalent to the wild-type receptor (12).
Here we show that similar to what was reported with
human chemokines, this mutant responds to murine
inverse agonists, but not the agonists. (Figure 1b).
Finally, we tested a mutant ([L91D]ORF74) (Figure 1a),
which has been deprived of its high constitutive activi-
ty (12). Murine and human agonists stimulated signal
transduction, but the inverse agonists had no effect, in
accordance with the fact that there is no constitutive
activity to suppress (Figure 1b). Taken together, these
results indicate that the wild-type ORF74 receptor and
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Figure 1
Regulation of ORF74 activity by human and murine CXC chemokines. (a) Diagram of ORF74 and its mutant forms. (b) Phosphatidyl inos-
itol turnover in transiently transfected COS-7 cells stimulated by human (open columns) or murine chemokines (filled columns). Values are
given in percentage of specific basal activity. Three columns are shown for each peptide corresponding to 0, 1, and 100 nM of peptide (from
left to right). WT-ORF74: Full, potent activation by the human agonist GROα as well as the murine homologue MIP-2, but not by KC, and
potent, efficient inhibition by both the murine and human IP-10 and SDF-1α. ∆22-ORF74: No significant effect of any murine or human
chemokine on the high constitutive signaling. L91D-ORF74: This mutant is fully and potently stimulated by both human GROα and the
murine MIP2, but there is no effect of either human or murine inverse agonists. R208H;R212H-ORF74: No stimulation by either murine or
human agonists, but inhibition of constitutive activity by both murine and human inverse agonists.
its mutant versions respond equivalently to human
chemokines and their murine orthologues.
Generation of transgenic mice expressing ORF74 mutants.
A number of founder transgenic mice expressing
each of the ORF74 mutants described above were
generated. The transgenes were driven by the hCD2
promoter, as described previously (7) and are referred
to as CDVG ([WT]ORF74), L91D ([L91D]ORF74
mutant), ∆22 ([∆22]ORF74 mutant), and, finally,
R2H ([R208H;R212H]ORF74 mutant) (Figure 2a).
Thirty-six transgenic founders were generated carry-
ing the L91D transgene; eleven founders carrying the
∆22 transgene, and nine founders carrying the R2H
transgene. Founders were monitored daily for devel-
opment of phenotypes and mated to generate trans-
genic lines. Seven lines were derived from L91D
founders, seven lines from ∆22 founders, and eight
lines from R2H founders. Expression of the different
transgenes was assessed by Northern blot analysis of
thymic RNA or by flow cytometric analysis of thy-
mocytes using a mAb against ORF74. A representa-
tive analysis of expression of the different transgenes
is shown in Figure 2 (b–d).
Elimination of the constitutive signaling activity of
ORF74 dramatically reduces disease incidence in trans-
genic mice. As reported previously, seven founders car-
rying the wild-type ORF74-encoded receptor were gen-
erated from pronuclear injections (7). Five independent
transgenic lines were obtained from six
founders. Strikingly, all animals in three
lines expressing ORF74 showed multi-
ple angiogenic lesions within 90 days of
life (Table 1). As described previously,
these lesions were located in the ears,
the tail, the nose, or the paws, and con-
sisted initially of bright, sharply bor-
dered erythematous plaques, which
eventually progressed to nodules and
subsequently to tumors (Figure 3d).
Tumors were common after 150–200
days of life and were often found in the
structures described above as well as in
muscles of the lumbar region.
To test if the constitutive activity of
ORF74 was essential for tumorigenesis
we studied transgenic mice expressing
the mutant L91D-ORF74. The basal
activity of this receptor (as measured by
PI turnover) in vitro is 18.9% of that
detected for WT-ORF74, which is
essentially similar to that found in cells
transfected with an empty vector (12).
Thirty-six independent transgenic
founders were created carrying the
L91D transgene. Twenty-five of these
founders were aged to 200 days and
euthanized. At necropsy there were no
signs of angiogenic lesions or tumors,
despite receptor expression in 10 of the
20 founders examined (data not shown). Next we
examined receptor expression in seven lines derived
from the L91D founders. Cell surface expression of the
mutated receptor could be detected in animals in four
of these lines (lines 13, 15, 18, and 20; Figure 2, b and
d), but no angiogenic lesions could be observed in ears,
tails, or limbs by 90 days of age (Table 1). The inci-
dence of angioproliferative disease in these animals
was significantly different from that observed in the
CDVG mice (P < 0.00036). Taken together, these
results indicate that the constitutive activity of ORF74
is an essential element in the pathogenesis of the 
KS-like disease in transgenic mice.
Deletion of the chemokine-binding domain of ORF74 pre-
vents the development of KS-like disease. To determine the
importance of the chemokine-binding domain in the
development of KS-like disease we studied transgenic
mice bearing the [∆22]ORF74 mutant (Figure 1a). This
mutant is unable to respond to both human (12, 15)
and mouse chemokines (Figure 1b), but preserves high
constitutive activity (basal activity is 90% of that
observed for WT-ORF74) (12). Eleven ∆22 founders
were generated. All these founders survived past 90
days of age and five past 400 days. Strikingly, none of
these mice developed angiogenic lesions or tumors. All
the founders were mated, and eleven lines were gener-
ated. Seven out of the eleven ∆22 lines expressed the
transgene by RNA analysis of thymic RNA (Figure 2b).
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Figure 2
Generation and expression analysis of ORF74 transgenic mice. (a) Schematic descrip-
tion of the transgenes CDVG, L91D, ∆22, and R2H. Mutant forms of ORF74 described
in Figure 1 were cloned into a vector containing the hCD2 promoter and locus control
region (LCR). (b) Northern blot analysis of thymic RNA from control and transgenic
mice. Shown are representative samples from CDVG (line 19), L91D (lines 15 and 13),
∆22 (lines 7 and 58), and R2H (line 24) animals. Lower panel shows the ethidium bro-
mide–stained RNA gels. (c) Histogram of ORF74 expression on thymic cells from con-
trol and CDVG (line 19) transgenic mice. Transgene expression is distinct and easily
detectable at the cell surface by flow cytometry. (d) Relative number of thymocytes
expressing ORF74, estimated by flow cytometry, in CDVG (lines 19 and 122), L91D
(line 13), and R2H (line 24). Bars represent average ± SD (n = 3). p, progeny.
When examined at 90 days of age, none of the animals
in these lines displayed angiogenic lesions (Table 1).
Thus, within the first 3 months of life there was a sig-
nificant (P < 0.0031) difference in the incidence of
angiogenic disease between ∆22 and CDVG animals.
Only one animal from line 58 developed a tumor on
the tail at 300 days of age. The absence of angioprolif-
erative lesions in the ∆22 mice suggests that chemokine
binding to ORF74 is necessary for development of 
KS-like disease in transgenic mice.
Selective ablation of agonist-induced stimulation reduces the
tumorigenic potential of ORF74. Having demonstrated
that both the constitutive activity and the chemokine-
binding domain of ORF74 are necessary for the devel-
opment of KS-like disease in mice, we focused next on
the following question: To what degree is the regula-
tion of ORF74 activity important for the development
of disease? As yet, we have been unable to generate a
mutant in which inverse agonist function is selective-
ly eliminated; but we have identified a mutant
([R208H;R212H]ORF74) (Figure 1a) that binds sever-
al murine chemokine ligands, has high constitutive
activity (basal activity at 89% of WT-ORF74), but
responds very poorly to agonist stimulation (12). Nine
transgenic founder animals carrying this transgene
(R2H) were generated, and eight expressing lines were
derived (Table 1). Transgene expression was ascer-
tained by both RNA analysis and flow cytometry (Fig-
ure 2, b and d). Only two of the nine founders devel-
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Table 1
Incidence of KS-like disease in ORF74 transgenic mice
Founders KS-like disease
CDVG 3/6 (50%)
∆22 0/11 (0%)
R2H 2/9 (22%)
L91D 0/25 (0%)
Lines
CDVG KS-like disease ∆22 KS-like disease R2H KS-like disease L91D KS-like disease
19 210/210 (100%) 7 0/13 (0%) 24 22/79 (28%] 13 0/50 (0%)
9 41/41 (100%) 53 0/5 (0%) 3 0/15 (0%) 15 0/10 (0%)
122 39/39 (100%) 1 0/2 (0%) 26 0/8 (0%) 18 0/1 (0%)
7 0/22 (0%) 58 0/2 (0%) 1 1/5 (20%) 20 0/1 (0%)
18 0/3 (0%) 60 0/1 (0%) 4 0/1 (0%)
61 0/1 (0%) 15 0/2 (0%)
66 0/1 (0%) 16 0/5 (0%)
28 0/1 (0%)
Animals were examined at 90 days of age for development of angiogenic lesions in the ears or limbs. Number of animals presenting lesions, number of total
animals examined, and penetrance of the phenotype are indicated.
Figure 3
Angiogenic and inflammatory lesions in CDVG, R2H and ∆22 trans-
genic mice. (a) Angiogenic lesions in the ear of a CDVG (line 19)
mouse. (b) Angiogenic lesions in the ear of a R2H (line 24) mouse.
(c) Erythematous, swollen, ulcerated ear lesions in a ∆22 (line 1)
mouse. (d) Tail tumor in a CDVG (line 19) mouse. (e) Tail tumor in
a R2H line 24 mouse. (f) Ulcerations and scales in the tail of a ∆22
(line 1) animal. (g) H&E-stained section of the tumor from the CDVG
mouse shown in d. The tumor is moderately pleomorphic, and many
spindle-shaped cells arranged in interlacing fascicles are present. Sev-
eral slitlike vascular spaces often containing erythrocytes are
observed. (h) H&E-stained section of the tumor from the R2H mouse
shown in e. The cellular composition and the arrangement of spin-
dle cells in fascicles is indistinguishable from that found in CDVG
mice (e). (i) H&E-stained section of the ear of the ∆22 animal shown
in c. The cellular infiltrate in inflamed ears consists mostly of granu-
locytes (eosinophils and neutrophils) and mononuclear cells.
oped KS-like disease. One founder (no. 23) had an ear
plaque that did not progress to nodules or tumors and
the other (no. 15) had an erythematous lesion that
progressed to a tail tumor after 150 days. Only two of
the eight R2H lines (no. 1 and no. 24) developed a 
KS-like disease, and within these lines the penetrance
of the phenotype was low (20% and 28%, respectively)
(Table 1). These angiogenic lesions (and tumors) were
histologically similar to those observed in mice
expressing the wild-type receptor (Figure 3, b, e, and h).
Interestingly, not only did a smaller fraction of mice
within the affected lines develop KS-like disease, but
also the severity of the disease was reduced when com-
pared with that seen in the mice expressing the wild-
type receptor. Taken together, the incidence of angio-
genic disease in R2H founders and lines was
significantly lower than that observed in the CDVG
founders and lines (P < 0.036). Based on these results,
we conclude that the mutations affecting the ability of
ORF74 to respond to agonists such as MIP-2 (and pos-
sibly other murine chemokines) reduce its ability to
induce angiogenic lesions and tumors in vivo.
The ORF74 chemokine ligands are expressed within the KS-
like lesions. The absence of KS-like disease in the ∆22
mice and the reduced penetrance of angiogenic phe-
notype in R2H mice at 90 days of age were highly sug-
gestive of a regulatory role for endogenous
chemokines in the development of disease. We there-
fore examined the expression of murine chemokine
ligands within lesional tissue of transgenic animals. As
shown in Figure 4, the CXC-ELR chemokines KC and
MIP-2 were both detected within angiogenic lesions of
most samples examined, but not in the control sam-
ples. In contrast, the non-ELR CXC chemokines IP-10
and SDF-1α were expressed in most lesions and in the
control samples. These results confirmed expression
of different forms of ORF74 and its ligands within
lesional tissue and raise the possibility of local modu-
lation by endogenous chemokines of receptor activity.
Inflammatory phenotypes are observed in CDVG, ∆22,
L91D, and R2H mice. Inflammatory lesions affecting skin
and, to a lesser extent, the joints and the intestinal tract,
were apparent in some of the transgenic mice but never
in wild-type littermates. Such lesions were observed in
one line of mice expressing the wild-type ORF74 recep-
tor, in all seven ∆22 lines with varying penetrance, and
in five out of the eight lines expressing the R2H trans-
gene. These lesions were not detected in any of the L91D
founders, but were seen in approximately 20% of ani-
mals of one of the four L91D lines (no. 13) after 120
days of age. In most cases the skin lesions ulcerated
spontaneously, giving rise to scabs on the tail, ears, and
face (Figure 3, c and f). Histologically, the skin lesions
were characterized by hyperkeratosis, acanthosis, and
inflammatory infiltrates rich in both polymorphonu-
clear and mononuclear cells (Figure 3i). Swollen joints
and rectal prolapse were more rarely observed.
Discussion
KS is an angioproliferative disease epidemiologically
linked to HHV8 (2, 16, 17). Among the many genes
encoded by HHV8 is ORF74, a constitutively highly-
active chemokine receptor that binds a number of CXC
chemokines (10). Surprisingly, expression of ORF74 is
sufficient to induce a KS-like disease in transgenic
mice, suggesting a central role for this receptor in the
pathogenesis of KS (7). In this study we investigated the
mechanisms associated with the induction of the
angioproliferative disease, focusing on the constitutive
versus regulated signaling properties of ORF74.
Experiments carried out in vitro have suggested that
the constitutive signaling activity of ORF74 is a pivotal
element in the induction of KS (5, 6, 9). To examine the
contribution of the constitutive activity of ORF74 to
the development of KS-like disease we generated sever-
al founders and transgenic lines carrying a mutated
form of ORF74 (L91D-ORF74) capable of ligand bind-
ing and activation, but deficient in constitutive signal-
ing. Despite expression of the mutant receptor at the
cell surface level, none of the transgenic mice developed
angiogenic lesions by 90 days of age. These results con-
firm that the constitutive signaling activity of ORF74
is required for the development of KS-like disease.
ORF74 has been optimized by HHV8 not only for
high constitutive signaling, but also for high-affinity
binding of a number of endogenous chemokines of its
host. Interestingly, the chemokines that act as agonists
on ORF74, i.e., further increase the signaling activity,
are all angiogenic chemokines, with GROα being the
most potent example (10, 11, 15, 18). Moreover, the two
chemokines (IP-10 and SDF-1α) that act as inverse ago-
nists, i.e., decrease the signaling toward basal level,
function as angiostatic chemokines in vivo (9, 10, 18).
Thus, both positive and negative modulation of the
high constitutive signaling activity of ORF74 by
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Figure 4
Expression of ORF74 and chemokines within lesions of transgenic mice.
RT-PCR analysis of distinct CXC chemokines and ORF74 in control and
transgenic tissues. ORF74 expression is detected in all transgenic sam-
ples, but not in control tissue. Expression of the ELR-chemokines KC and
MIP-2 is detected within tumors of CDVG and R2H mice and in inflam-
matory lesions of ∆22 transgenic mice. The non-ELR chemokines 
SDF-1α and IP-10 are expressed in both transgenic and control samples.
endogenous chemokines could be important for the
development of the highly vascularized lesions. This
hypothesis is supported by several observations report-
ed here. First, deletion of the far N-terminal segment of
ORF74, which deprives the receptor of its ability to
bind any chemokine, prevented the formation of the
KS-like tumors in the transgenic animals, despite the
fact that the mutant receptor still displayed unaltered
high constitutive signaling activity. Second, expression
of the mutant [R208H;R212H]ORF74, which pre-
served high constitutive activity but failed to respond
to the agonist chemokines GROα and its murine
orthologue MIP-2, was associated with reduced pene-
trance and severity of the KS-like disease. Third, expres-
sion of the angiogenic and angiostatic chemokines,
which have been shown to modulate ORF74 activity,
was detected within the lesional tissue of the transgenic
mice. Taken together, these results indicate that mod-
ulation of the high constitutive activity of ORF74 by
endogenous chemokines is an important factor in the
development of a KS-like disease in mice.
Expression of ORF74 and its mutant forms in trans-
genic mice was also associated with development of
inflammatory conditions affecting predominantly the
skin and, to a lesser extent, the joints and gastrointesti-
nal tract. These conditions may have been caused by cells
expressing these receptors within the inflammatory sites.
Alternatively, they may have resulted from expression of
the receptor(s) within thymic cells. This hypothesis is
based on our recent observations that thymic develop-
ment is affected in many of the transgenic mice report-
ed here (D. Manfra, unpublished observations). Altered
thymic development may have led to a systemic immune
dysfunction favoring the development of the inflamma-
tory conditions, as documented in several other models
(19–21). Further studies are underway to define the
mechanistic basis of these inflammatory phenotypes.
Results presented here point to co-optation and opti-
mization by the HHV8 of basic signal transduction
pathways triggered by chemokine receptors, in particu-
lar those implicated in angiogenesis. Several studies in
the literature have implicated chemokines of the CXC-
family in angiogenesis, angiostasis, tumor growth, and
tumor regression (for review see ref. 18). The CXC-
chemokines containing the ELR-motif have been shown
to be angiogenic factors in vitro and in vivo and to be
capable of enhancing tumor growth of immortalized
cells, whereas the ELR-lacking CXC-chemokines have
been shown to have opposite effects in vivo (11, 18,
22–25). Here we find that modulation or fine-tuning of
the signaling activity of ORF74 by endogenous angio-
genic chemokines is required for the development of
highly vascularized tumors. ORF74 may thus represent
a molecular switch to initiate a program of gene expres-
sion that will affect multiple functions, including angio-
genesis. One of the genes affected by ORF74 expression
is the potent angiogenic factor VEGF, whose expression
has been demonstrated in endothelial and fibroblast
cells transfected with ORF74, within KS lesions, and
within ORF74-induced tumors in transgenic mice (5, 7,
26). Other likely candidates would be the proinflam-
matory cytokine IL-1β and basic fibroblast growth fac-
tor. These molecules, which are also frequently detect-
ed within KS lesions, are induced in cells transfected
with ORF74 (4, 27). Because we cannot formally assume
that ORF74 signaling will result in activation of the
same genes in transfected cells and in transgenic cells, it
will be important to examine the expression of the genes
downstream of ORF74 in vivo. These studies will cer-
tainly contribute to characterization of the molecules
involved in the angioproliferative disease described here.
Expression of chemokines by human tumor cells and
tumor-infiltrating leukocytes has been amply docu-
mented in the literature, but it is unclear why they
should be produced under these circumstances. Several
potential roles have been proposed, including direct con-
trol of cellular proliferation, control of angiogenesis, and
regulation of macrophage and dendritic cell function
(28). Here we present evidence to suggest a novel role for
chemokines in tumor biology, namely, regulation (by
CXC chemokines) of the activity of a chemokine recep-
tor oncogene. This virally encoded chemokine receptor
acts as a nonconventional oncogene to promote pro-
duction of paracrine factors that drive proliferation of
endothelial cells and recruitment of inflammatory cells
(7, 29). It is unclear whether local chemokines, besides
affecting ORF74 activity, affect angiogenesis through
interaction with other receptors, such as CXCR2,
CXCR3, and CXCR4. These chemokine receptors are
expressed in the vascular endothelium and have been
implicated in angiogenesis (30–33). In this context, it will
be of interest to investigate if chemokines and their
receptors influence angiogenesis in normal and tumor
settings, primarily through paracrine mechanisms.
In summary, the results described here implicate
chemokines in the development of KS-like lesions in
transgenic mice. We propose that modulation of
ORF74 activity by chemokines may also represent a key
step in the generation of KS in humans and suggest
that the model described here represents the first
example of a chemokine-driven neoplastic condition.
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